Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01105507

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Cryopyrin Associated Periodic Syndrome Clinical Trial

Official title:
An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Clinical Trial Summary

This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Cryopyrin Associated Periodic Syndrome
  • Cryopyrin-Associated Periodic Syndromes
  • Syndrome
Clinical Trial Details
NCT number NCT01105507
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date August 2010
Completion date May 12, 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT04856540 - Adult Outcomes of Children With CAPS
Completed NCT04086602 - Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334 Phase 1
Not yet recruiting NCT05292768 - Are Mast Cells Involved in Autoinflammatory Diseases
Completed NCT05812781 - A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome Phase 2
Completed NCT05186051 - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) Phase 2